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Background: Tuberculosis is a leading cause of death among people living with human
immunodeﬁciency virus. In sub-Saharan Africa, tuberculosis accounts for more than 78%
of  all deaths among people with human immunodeﬁciency virus.
Objectives:  To assess tuberculosis treatment outcome and the associated factors in adult
tuberculosis/human  immunodeﬁciency virus co-infected patients in four public hospitals
of  eastern and southern zone of Tigray region, Ethiopia.
Methodology: Institution based cross-sectional study design was used to examine secondary
data  from tuberculosis/human immunodeﬁciency virus co-infected patients attending four
public hospitals of eastern and southern zone of Tigray, from January 2009 to August 2011.
Systematic  random sampling technique was used to select individual patient cards from
the  respective hospitals. Univariate analysis and multivariate logistic regression modeling
was  used to assess the impact of each variable in predicting treatment outcome.
Results: Out of 342 patients included, 199 (58.2%) patients completed treatment, 43 (12.6%)
patients  were cured, 88 (25.7%) died, 7 (2%) defaulted, and 5 (1.5%) patients failed treatment.
Treatment  success rate was around 71%. In the multivariate logistic regression analysis
the  factors that were strongly associated with unfavorable tuberculosis treatment out-
comes  were WHO  stage IV (AOR = 3.2, CI = 1.58–6.82, p-value = 0.001), age greater than 45
years  (AOR = 6.08, CI = 2.28–16.23) and baseline CD4 count less than 200 cells/L (AOR = 6.19,
CI  = 2.28–16.89, p-value = 0.001).
Conclusion: The rate of treatment success in this study was lower than the rate newly rec-ommended  by WHO.  Ther
rates  of both diseases.
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Introduction
Globally it is estimated that almost 33% of all people living
with  HIV are co infected with TB and among these one in
four  deaths is due to TB. Where as in sub-Saharan Africa the
co  infection reaches for more  than 70%. People with HIV are
six  times more  likely to die during TB treatment. In the year
2009,  approximately 400,000 people died of HIV-associated TB.
In sub-Saharan Africa, it accounts for more  than 78% of HIV-
related  TB deaths.1
According to the 2008 World Health Organization (WHO)
report,  the HIV epidemic has completely destabilized TB con-
trol  in regions with high rates of HIV. For example, in one
community outside of Cape Town, South Africa, TB patient
case  load increased six-fold between 1996 and 2004. The rates
of  TB in this community is over 150-fold higher than the
national  rates in many  high-income countries, and this has
been  replicated right across southern Africa.2
Ethiopia is one of the highly affected countries by TB/HIV
co-epidemic and ranked 7th among the 22 high TB burden
countries in the world. The reported prevalence of TB/HIV
co-infection has varied according to different authors and
study  site. However, the 2008 WHO  Global Report estimates
that  in Ethiopia 40% of TB patients tested for HIV turned out
positive.3
TB and HIV co-infection are associated with special diag-
nostic  and therapeutic challenges and constitute an immense
burden  on healthcare systems of heavily infected countries
like  Ethiopia.3 TB/HIV co-infected patients have lower qual-
ity  of life in all domains as compared to HIV infected patients
without  active TB.4
Despite the availability of effective drugs for treating both
HIV/AIDS  and TB, the co-management of TB and AIDS has
proved  very difﬁcult largely because of non-adherence due
to  high pill burden, drug-drug interaction and side effects.
There  is also a worrisome convergence of multi-drug resis-
tant  or extensively drug-resistant tuberculosis in the setting
of  HIV infection causing a high mortality rate. To overcome
this  problem the WHO  recommends that Highly Active Anti-
retroviral  therapy (HAART) should be given as early as possible
within  eight weeks of TB treatment initiation regardless of CD4
count.5
There is also evidence that early initiation of ART in people
living  with HIV signiﬁcantly improves survival of co-infected
patients and reduces excess risk for opportunistic disease or
death, besides having a signiﬁcant role in TB prevention.6,7
Studies from different countries have documented the
treatment success of anti-TB regimen ranging from 30%8 to
83%.9 The treatment outcomes have signiﬁcant association
with  socio-demographic attributes8,10 like age, sex, and mar-
ital  status, in addition to clinical variables like TB category,
HIV/AIDS co-infection and late ART initiation.11–13
So far, there is limited information available about predic-
tors  of treatment outcomes of TB patients co-infected with
HIV  in Ethiopia. Therefore, the aim of this study was  to assess
TB  treatment outcomes categorized as favorable or unfavor-
able  outcomes among HIV infected patients receiving anti-TB
treatment  and to identify the associated predictors for these
treatment  outcomes. 0 1 5;1  9(1):47–51
Methodology
Study  area  and  population
Tigray is the northern region of Ethiopia covering an area of
54,569.25  km2. In 2007, the population of the region was  4.3
million  out of which 81% are living in rural area. Currently,
a  total of 14 public hospitals (one Referral, six Zonal and the
remaining  are District hospitals), 209 health centers and 538
health  posts are available in Tigray. All of the hospitals are
providing  comprehensive service for patients with TB/HIV co-
infection.
This study was conducted in four public hospitals located
in  Eastern and Southern zones of the region: Adigrat, Wukuro,
Lemlem  Karl and Alemata hospital. The study population was
all  TB/HIV co-infected adult patients registered in one of the
above  four hospitals and on TB treatment from January 2009
to  August 2011.
Study  design
Institutional based cross-sectional study design was used to
examine TB treatment outcomes of HIV co-infected patients
attending the afore-mentioned public institutions.
Population
Patients aged ≥15 years, TB-HIV co-infected who were  treated
for  at least TB, having complete record of treatment outcomes
were  included in the study. Treatment outcomes are catego-
rized  as favorable (cured, treatment complete) or unfavorable
(died,  defaulted or failed).
Sample  size  and  sampling  methods
Sample size was  determined using a single population pro-
portion  formula with 95% conﬁdence interval and 5% margin
of  error, assuming 50% favorable treatment outcomes among
TB/HIV  subjects. Since the population was less than 10,000
the  sample was  inﬂated by a correction factor and ended up
in  342 units. Then, the calculated sample size was  distributed
based  on population proportion to size. All TB/HIV infected
patients who registered for anti-TB treatment during January
2009–August  2011 were used as a sampling frame for selec-
tion.  Systematic random sampling method was  used to select
individual  patient cards from the respective hospitals.
Data  collection  and  management
Data were  collected using prepared data extraction format
(checklist). The format was  developed by considering vari-
ables  to be studied which were found in the registration book,
follow-up  card of the patients, and baseline studies. It was
pre-tested  and updated. Data collectors and one TB clinic
head  nurse/health ofﬁcer from each hospital received a one-
day  training that emphasized exclusion of incomplete cards,
inclusion  and exclusion criteria, and recording the exact infor-
mation  from the follow-up card.
Patient records were identiﬁed from the database or TB
treatment follow-up medical record cards. One facilitator from
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Table 1 – Association of independent factors (predictive
variables) including ART category, WHO  HIV/AIDS stage,
baseline  CD4 count, and socio-demographic attributes
with  the treatment success (dependent variable).
Variables of TOCa (B) Coefﬁcient Sd. Err. Adj. OR (95%CI)
Age category
15–30 0.15 0.45 0.86 (0.36–2.07)
31–44  1.00 1.00 1.00
45+  1.95 0.52 6.08 (2.28–16.23)
Functional  status
Ambulatory −0.11 0.61 0.89 (0.27–2.96)
Bedridden  1.00 1.00 1.00
Workable  −2.96 0.49 0.05 (0.02–0.14)
Baseline  CD4 count
≤200  cells/L 1.82 0.51 6.19 (2.27–16.89)
>200  cells/L 1.00 1.00 1.00
WHO  stage category
Stage  3 1.00 1.00 1.00
Stage  4 1.16 0.39 3.20 (1.58–6.82)
ART  initiation category
On  ART 1.00 1.00 1.00
Not  on ART 1.23 0.39 3.42 (1.59–7.36)
Bwt  −0.17 0.05 0.83 (0.76–0.94)
Cons  −2.06 0.75b r a z j i n f e c t d i
ach hospital card room was  used to identify individual cards.
he  recorded (collected) data were checked for completeness
y  the principal investigators for its completeness on a daily
asis.
ata  analysis
ata were  entered, cleaned and analyzed using SPSS ver-
ion  16. Descriptive statistics aimed to summarize patients’
haracteristics across different categories of the independent
ariables. The effect of categorical and continuous predictor
ariables on the outcome of interest were checked using nor-
ality  test of the distribution of values of the continuous
ariables, collinearity statistics and interaction between the
igniﬁcant  variables.
Multicollinearity among predictor variables was assessed
sing  the variance inﬂation factor (VIF) and tolerance (1/VIF).
hose  variables with greater than 10 VIF or less than 0.1
olerance  values were  considered as having no collinearity.
IF  Model adequacy was  checked and assessed using −2 log
ikelihood,  Cox & Snell R Square, Nagelkerke R Square, and
oodness-of-ﬁt.
To  assess the relation of each predictor variable and the
reatment outcome, univariate logistic regression model was
sed.  Those variables with a p-value of less than 0.05 were
ncluded  in the multivariate logistic regression model by back-
ard  stepwise entry method for assessing predictive power of
hose  variables. A chi-square test was  also performed to assess
he  association between the dependent and individual inde-
endent  variables and combination of them to identify the
igniﬁcance of predictor variables.
thical  considerations
thical clearance was  obtained from the Institutional Review
oard  (IRB) of the College of Health sciences, MU. Sup-
orting letters were  obtained from Tigray Health Bureau
o  the selected study Hospitals. Hospital Managers were
ontacted and permission was  secured. Name and other
dentiﬁers of patients were not recorded on the question-
aires. The ﬁlled documents were  archived properly to
nsure  conﬁdentiality and no third person had access to the
ata.
esult
ocio-demographic  characteristics
 total of 342 HIV/TB co-infected patients under TB treatment
ere  included; 186 (54.4%) males, mean age 34 years (95%
I  = 33.01–35.12; SD = 9.87), being 35 years (95% CI = 33.7–36.9,
D  = 10.2) for males and 33 years (95% CI = 31.5–34.3, SD = 9.4)
or  females. Most of them (83.6%) were in the productive age
roup  (15–44 yrs). The mean baseline weight was  44.8 kg (95%
I  = 44.02–45.5, SD = 6.9). Three hundred and eight (90.1%) par-
icipants  were Orthodox followers, 181 (52.9%) were  married;
09  (61.1%) study subjects attended primary school and 98
28.6%)  were employed.a Bwt, baseline weight; TOC, treatment outcome category.
Analysis  of  the  factors
The factors with a p-value less than 0.05 were  included in
multivariate logistic regression analysis and if the 95% CI
of  the odds ratio excluded one. Not to be on ART had 3.42
times  higher risk of having unfavorable treatment outcome
than  those patients on ART before starting TB treatment (Adj.
OR  = 3.42, 95% CI = 1.59–7.36, p-value = 0.002; Table 1).
Discussion
All of the public hospitals and most of the public health centers
of  Tigray had implemented the TB/HIV integrated activities to
tackle co-infection in that region of the country. Implementa-
tion  of these activities also addresses areas of mutual interest
for  control programs  of the two diseases and ultimately con-
tributes  immensely to address this dual epidemic that has had
a  tremendously negative impact on TB treatment outcomes.
The  rate of treatment success (cured or complete) was
lower  (71%) than the 75% to 85% observed in other studies
conducted in Districts of southern India, teaching hospitals in
southern India, South Africa in 2009 during the ART rollout,
as  well as the target rate aimed by the national TB and Lep-
rosy  control program of Ethiopia.9,11,12,14 Nonetheless, our rate
was  higher than the 29.5%–66.3% found in other studies con-
ducted  in Gonder teaching hospital, north west Ethiopia, and
university  college hospital, Ibadan, Nigeria.8,15|
The death rate (25.7%) of the study group was  higher when
compared to other studies conducted in teaching hospital
of  southern India, south Africa during the ART rollout and
Gonder  teaching hospital.8,9,12 On the contrary, it was lower
than  the 29.95% to 30% found in other studies conducted
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in Addis Ababa public health centers and districts of south-
ern  India.10,11 However, it was  similar to death rate (25.7%)
encountered in the study conducted in Gombe state, Nigeria.16
This implies that it needs further reconsideration of the guide-
lines  and the collaborative activity from sectors and other
stakeholders to improve the favorable treatment outcome.
The  default rate (2%) seen in the study was lower com-
pared  to rates (8.2%–18.3%) found in other studies conducted
in  Gonder teaching hospital, Ethiopia and teaching hospi-
tals  of south India.8,9 The treatment failure rate (1.5%) of the
present  study was  lower than the rates observed in other study
conducted  at the university college hospital, Ibadan, Nigeria
(10.6)15 and at the teaching hospital south India (2.2%).9 It
was  higher than the rate found in Gonder teaching hospital
Northwest Ethiopia (0.2%).8
The rates across the studied hospitals Adigrat, Alamata,
Wukuro, and Lemlem Karl were  respectively 8.8%, 12.7%,
16.7%,  and 17.5% for cure; 52.8%, 57.6%, 59.5%, and 70.2% for
completeness; 1.6%, 3.4%, 2.4%, and 0% for defaulting; 35.2%,
25.4%,  16.7%, and 12.3% for death; and 1.6%, 0.8%, 4.8%, and 0%
for treatment failure. The results shown in Lemlem Karl hos-
pital  were  better when compared to the other three hospitals
and  this ﬁnding warrants further investigation.
The overall treatment success rates were 87.8%, 76.3%,
70.3%,  and 61.6%, respectively, in Lemlem Karl hospital,
Wukuro hospital, Alamata hospital, and Adigrat hospital. This
suggests that the treatment success rate varies among hospi-
tals.  This may  be due to difference in human resource quality
and  quantity, and availability of diagnostic facilities. The fac-
tors  associated with the observed difference warrant further
investigation.
Even  though it was  not signiﬁcant in this study, the impor-
tance  of chemoprophylaxis, such as CPT, to prevent other
OIs  may  also play a signiﬁcant role in avoiding deaths par-
ticularly  when access to ART is limited, as in developing
countries.11 Though WHO  and Ethiopian National guidelines
recommend that all HIV-infected patients diagnosed with TB
should  receive CPT, 26% of the patients had not received CPT
at  time of initiation of anti-TB treatment in the descriptive
study.
In  the multivariate logistic regression analysis, patient’s
age,  ART initiation, baseline CD4 category, WHO  stage,
functional status, and baseline weight were signiﬁcantly asso-
ciated  with unfavorable TB treatment outcome. Age category
was  independently associated with unfavorable TB treatment
outcome  in this study. Patients with age ≥45 years had signif-
icantly  higher probability of death compared to patients aged
<45  years (AOR = 6.08, 95% CI = 2.28–16.23). This was  consistent
to  other studies from developing countries. A study conducted
in  South Africa identiﬁed that being aged ≥41 years signiﬁ-
cantly  increased the risk of unfavorable treatment outcome of
TB/HIV  co-infected patients (RR = 3.2, 95% CI = 2.4–7.7).12 Thus,
clinicians  working in TB/HIV clinics should give closer atten-
tion  to elderly patients to enhance the desired outcomes of
the  TB/HIV collaborative activities.
No initiation of ART was  found to be an independent risk
factor  for unfavorable TB treatment outcomes. Those patients
who  were not on ART had 3.42-fold increase in risk of unfa-
vorable  outcomes (AOR = 3.42, 95% CI = 1.59–7.36). Similarly, a
study conducted in South India showed that not to be on ART 0 1 5;1  9(1):47–51
had 4.9-fold increase in risk for unfavorable treatment out-
come  (AOR = 4.90, CI = 1.85–12.96).11 There is enough evidence
showing that patients with TB and HIV who did not receive
ART  had a signiﬁcantly higher risk of unfavorable treatment
outcome, particularly death.11,12,17
Despite the apparent beneﬁt associated with ART, only
48%  (164) of the HIV-infected TB patients received ART in
our  study. Similarly, most HIV-infected TB patients in many
developing  countries still cannot access ART primarily due
to  economic barriers and limited coverage.11 So these ﬁnd-
ings  highlight the importance of expanding and improving
delivery of ART services as a priority and reconsideration of
the  program guidelines for ART initiation in HIV-infected TB
patients.
In  this study, baseline body weight was signiﬁcantly asso-
ciated  with higher unfavorable treatment outcome. A 1 kg
increase  in baseline weight was associated with 17% decrease
in  the risk of unfavorable outcome (AOR = 0.83, 95% CI,
0.77–0.94). Similar ﬁnding was  observed in South India, in
which  body weight at initiation of anti-TB treatment was  a sig-
niﬁcant risk factor of death during anti-tuberculosis treatment
period  (19).17 Therefore, it might be important to reinforce
the  existing DOTS program to include nutritional support for
underweight  patients in order to achieve better treatment out-
come.
Conclusion
There was  high rate of death (25.7%) or overall unfavor-
able treatment outcome (death, defaulting and failure = 29.2%)
among  TB/HIV co-infected. This is a serious public health con-
cern  that needs to be addressed. The independent risk factors
for  unfavorable treatment outcome found in this study were
non-initiation of ART before the initiation of anti-TB treat-
ment,  having low baseline weight, being older, having low
baseline  CD4 count (less than 200 cells/L), to be at WHO  stage
IV,  and having bedridden or ambulatory functional status.
Based  on these ﬁndings we recommend that governmen-
tal  and non-governmental organizations, local managers and
other  stakeholders involved in TB/HIV management should
facilitate  for implementation and enforce early application of
the  new WHO  Guidelines that recommend that any patient
with  CD4 count less than 350 cells/L should start ART
to  improve the treatment outcome of TB/HIV co-infected
patients.
There should be support and careful follow-up for older
patients. There should be early detection and treatment of
opportunistic infection, especially TB for those in WHO  stage
IV,  e.g. strengthening nutritional support like plump net to
those  with low baseline weight at the initiation of TB treat-
ment.  In addition, early detection of TB cases in HIV-infected
patients should be strengthened in order to improve treatment
outcome.
Limitation  of  the  studyThe major limitation of the study was related to the use
of  secondary data. As different literature pointed out, there
are  factors assumed to impact on treatment outcome of
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B/HIV co-infected patients, which may  not be available in the
econdary  data, such as alcohol consumption and cigarette
moking. There were  also missing values of the predictor vari-
bles.  However, we  minimized the risk of incomplete data by
aving multiple source of information (registration and card)
or  independent and dependent variables and by limiting the
bjective  to those important variables that could be collected
rom  the sources. The study used all forms of TB due to lack
f  enough patients with smear-positive pulmonary TB. The
xact  tools used to diagnose other forms of TB were  difﬁcult
o  ascertain.
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